| Brand | Abnova |
| Product type | Primary antibodies |
| Reactivity | Human,Mouse |
| Host species | Mouse |
| Applications | IP,ELISA,WB-Ce |
| Brand: | Abnova |
| Reference: | MAB0056 |
| Product name: | NFKBIA (phospho S32/S36) monoclonal antibody, clone 39A1413 |
| Product description: | Mouse monoclonal antibody raised against synthetic phosphopeptide of NFKBIA. |
| Clone: | 39A1413 |
| Isotype: | IgG1 |
| Gene id: | 4792 |
| Gene name: | NFKBIA |
| Gene alias: | IKBA|MAD-3|NFKBI |
| Gene description: | nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
| Immunogen: | Synthetic phosphopeptide corresponding to residues surrounding S32/S36 of human NFKBIA. |
| Form: | Liquid |
| Recommend dilutions: | The optimal working dilution should be determined by the end user. |
| Storage buffer: | In PBS (0.05% BSA, 0.05% sodium azide) |
| Storage instruction: | Store at 4°C. For long term storage store at -20°C. Aliquot to avoid repeated freezing and thawing. |
| Note: | This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
| Product type: | Primary antibodies |
| Host species: | Mouse |
| Antigen species / target species: | Human |
| Reactivity: | Human,Mouse |
| Application image: | ![]() |
| Application image note: | Jurkat cells were treated for 30 min with 100 ug/mL ALLN (N-Acetyl-Leu-Leu-Norleucinal; a Calpain inhibitor and also proteasome inhibitor that prevents IkBa dephosphorylation) followed by incubation with (lanes 2 & 4) or without 1 nM TNF-a (1 & 3). The membranes were blotted with NFKBIA monoclonal antibody, clone 39A1413 (Cat # MAB0056) (lanes 1 & 2) or NFKBIA monoclonal antibody, clone 6A920 (Cat # MAB0057) (that recognizes both non-phospho and phosphorylated forms of IkBa) and immunoreactivity was detected by ECL. The data shows that Cat # MAB0056 detects specifically the phosphorylated form of NFKBIA. |
| Applications: | IP,ELISA,WB-Ce |
| Shipping condition: | Dry Ice |
| Publications: | Cardioprotection afforded by inducible nitric oxide synthase gene therapy is mediated by cyclooxygenase-2 via a nuclear factor-kappaB dependent pathway.Li Q, Guo Y, Tan W, Ou Q, Wu WJ, Sturza D, Dawn B, Hunt G, Cui C, Bolli R. Circulation. 2007 Oct 2;116(14):1577-84. Epub 2007 Sep 4. |